68Ga-DOTATOC-avid lymphadenopathies induced from COVID-19 mRNA vaccination

Pudis, Michal; Conejero, J.L. Vercher; Marcuartu, Juan José Martín; Romera, M. Cortés

doi:10.1093/jjco/hyab129

Cited by 7 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After excluding 74 articles for the reasons stated in Figure 1 , and with the addition of 5 articles identified from the reference lists of articles, 39 articles were included in this review and 21 COVID-19 studies were included in the pooled analysis. A total of 25 studies [ 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ] were relevant to the COVID-19 vaccine and 14 studies [ 7 , 8 , 9 , 10 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ] were related to non-COVID-19 vaccines.…”

Section: Resultsmentioning

confidence: 99%

“…The 25 studies were published by authors from countries including Germany [ 18 ] ( n = 1), Israel [ 22 , 37 ] ( n = 2), Japan [ 26 ] ( n = 1), Portugal [ 20 ] ( n = 1), Qatar [ 31 ] ( n = 1), Singapore [ 32 , 33 ] ( n = 2), South Korea [ 27 , 30 , 39 ] ( n = 3), Spain [ 23 , 24 , 41 ] ( n = 3), Switzerland [ 21 ] ( n = 1), the United Kingdom [ 36 ] (UK) ( n = 1), and the United States of America [ 25 , 28 , 29 , 34 , 35 , 38 , 40 , 43 ] (USA) ( n = 8). Most studies are case reports ( n = 12, 48.0%), followed by case series ( n = 9, 36.0%), retrospective studies ( n = 3, 12.0%), and not reported in one study (4.0%).…”

Section: Resultsmentioning

confidence: 99%

“…Most of these patients were females (14/19, 73.7%). All patients had a prior history of malignancy, with a history of melanoma [18,40,42] [41] and renal cell carcinoma [35]. Most cases were associated with the Pfizer-Bio-Ntech vaccine, with equal proportions associated with the first and second dose (31.6%).…”

Section: Subclinical Lymphadenopathy Detected On Imaging (Sldi)mentioning

confidence: 99%

See 2 more Smart Citations

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

Chua

Takano

2022

JCM

View full text Add to dashboard Cite

COVID-19 vaccine-associated lymphadenopathy (C19-VAL) is increasingly encountered with the widespread use of the vaccine in controlling the outbreak. We aim to characterize the pathological findings of COVID-19 and non-COVID-19 vaccine-associated lymphadenopathy (NC19-VAL). A search for studies that reported pathological findings in vaccine-associated lymphadenopathy on PubMed and Google Scholar was performed on December 11, 2021. C19-VAL studies were pooled for analysis. These studies were split into clinical lymphadenopathy (CL) and subclinical lymphadenopathy detected on imaging (SLDI) for subgroup analysis. A total of 25 studies were related to COVID-19 vaccines, and 21 studies were included in the pooled analysis. The pooled analysis included 37 patients with a mean age of 47.8 ± 19.1 years old, and 62.2% were females. The mean duration from last vaccination to development of CL/SLDI was 14.5 ± 11.0 days. Most were diagnosed as reactive or negative for malignancy (28/37, 75.5%), followed by Kikuchi–Fujimoto disease (KFD) (3/37, 8.1%), florid lymphoid hyperplasia (2/37, 5.4%), and granulomatous inflammation (2/37, 5.4%). Metastases were reported in two patients with a history of malignancy (2/37, 5.4%). Cases with florid lymphoid hyperplasia and KFD were younger than those with reactive changes. A total of 14 studies were related to non-COVID-19 vaccines. Caseating granulomatous inflammation was reported in BCG vaccine-associated lymphadenopathy, while other vaccines were associated with reactive lymphoid hyperplasia, florid post-vaccinal reactions, and KFD. Although most C19-VAL cases were reported as reactive or negative for malignancy, other diagnoses included florid lymphoid hyperplasia, KFD, and granulomatous inflammation. Metastases were reported in lymphadenopathy of patients with a history of malignancy, who had been incidentally vaccinated. In conclusion, C19-VAL can yield different histopathological diagnoses when sampled, most of which require clinical and radiological correlation for optimal patient management.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Subclinical Lymphadenopathy Detected On Imaging (Sldi)mentioning

confidence: 99%

See 1 more Smart Citation

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

Chua

Takano

2022

JCM

View full text Add to dashboard Cite

show abstract

“…Patients found with bilateral nodal SSTR uptake (axillary and/or supraclavicular) post vaccination, also had at least two doses of the vaccine on alternate deltoid muscles [ 9 , 11 ]. Our reported patient had only one dose at the time of diagnostic imaging, in keeping with the unilateral findings.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

Kolade

Ayeni

Brink

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

SARS-CoV-2 (COVID-19) vaccination numbers are globally increasing. Therefore, an increased chance exists that patients undergoing Peptide Receptor Radionuclide Therapy (PRRT) or diagnostic radionuclide imaging for Neuroendocrine Tumours (NETs) may have recently received vaccination. We report the imaging findings of two NETs patients, A—following [ 177 Lu] Lu-DOTATATE PRRT post therapy planar scintigraphy and single photon emission computed tomography with computed tomography (SPECT/CT), and B—following [ 68 Ga]Ga-DOTA-NOC positron emission tomography with computed tomography (PET/CT) respectively. Both studies were done few days after COVID-19 vaccination. Patient A showed a new focus of uptake in the left deltoid muscle; and Patient B showed uptake in the left deltoid and a left axillary lymph node. Nuclear Physicians need to be aware of pitfalls with somatostatin receptor radionuclide imaging post-vaccination to ensure accurate interpretation, as well as dosimetric considerations with vaccine-related post-therapy uptake.

show abstract

“…After COVID-19 vaccination, uptake in ALN was observed with 68 Ga-DOTATATE ( 88 , 147 – 149 ), 68 Ga-DOTATOC ( 150 , 151 ), 18 F-fluciclovine ( 152 , 153 ), 68 Ga- or 18 F-PSMA ( 88 ), 18 F-rhPSMA-7.3 PET/CT ( 154 ), FCH ( 155 – 157 ), 11 C-choline ( 100 ), 18 F-florbetaben ( 158 ), and 18 F-DOPA ( 88 ). Positive FDG and 68 Ga-DOTATATE ALN uptake, respectively, was confirmed in 45 and 55% of the study cohort, which was a much higher incidence than that of 68 Ga- and 18 F-PSMA (0.3%) ( 88 ).…”

Section: Non- 18 F-fluorodeoxyglucose Positron Emi...mentioning

confidence: 99%

Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data

Minamimoto

2022

Front. Med.

View full text Add to dashboard Cite

The COVID-19 pandemic has forced people to significantly change their lifestyles and attitudes, and has greatly burdened healthcare delivery systems worldwide. The redistribution of the medical delivery system to maintain normal medical care while responding generously to COVID-19 is a continuing challenge that weighs heavily on medical institutions. Among imaging modalities, chest X-rays and computed tomography (CT) examinations have clearly made a large contribution to treatment of COVID-19. In contrast, it is difficult to express the standpoint of nuclear medicine examinations in a straightforward manner, as the greatest emphasis in this modality has been on how necessary medical care can continue to be provided. Many clinical reports of nuclear medicine examinations related to COVID-19 have been published, and knowledge continues to accumulate. This review provides a summary of the current state of oncology and cardiology positron emission tomography (PET) examinations related to COVID-19, and includes preparation of the nuclear medicine department, trends in PET examinations, specific imaging findings on 18F-fluorodeoxyglucose (FDG) PET/CT, imaging of complications of COVID-19, PET tracers other than FDG, and the effects of vaccines on PET imaging findings.

show abstract

68Ga-DOTATOC-avid lymphadenopathies induced from COVID-19 mRNA vaccination

Cited by 7 publications

References 0 publications

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data

Contact Info

Product

Resources

About